LAWRENCE, Mass., Aug. 10, 2012 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, will present at the Canaccord Genuity 32nd Annual Growth Conference on Tuesday, August 14th, at 4:30 p.m. ET. A webcast of the event will be made available at http://ir.nxstage.com/ at the time of the presentation.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Mr. Burbank's plans to present at this conference. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.
Contact: Kristen K. Sheppard, Esq. Investor Relations firstname.lastname@example.org
SOURCE NxStage Medical, Inc.